This session explores the integration of psychedelic-enhanced neuroplasticity into longevity medicine as a clinically governed pathway to reduce allostatic load and support healthy ageing. Drawing on early clinical experience, it outlines a structured psychedelic-assisted psychotherapy (PAP) model embedded within stress physiology, behavioural profiling, and longevity biomarkers, highlighting preliminary outcomes related to behavioural flexibility, emotional regulation, and sustainable lifestyle change.